![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Dong Bang Future Tech & Life Co., Ltd. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Entecavir monohydrate, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2018-093 - Rev 00
This Chemical Type CEP, issued on April 09, 2020, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2815 associated with this CEP further emphasizes